BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 16988515)

  • 41. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
    Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
    Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification.
    Keiser O; Fellay J; Opravil M; Hirsch HH; Hirschel B; Bernasconi E; Vernazza PL; Rickenbach M; Telenti A; Furrer H;
    Antivir Ther; 2007; 12(8):1157-64. PubMed ID: 18240856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
    Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
    Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
    J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects on infants of potent antiretroviral therapy during pregnancy: a report from Spain.
    Bellón Cano JM; Sánchez-Ramón S; Ciria L; León JA; Gurbindo D; Fortuny C; Bertrán JM; Ruiz Contreras J; Ramos JT; Asensi O; Mur A; Resino R; Muñóz-Fernández MA
    Med Sci Monit; 2004 May; 10(5):CR179-84. PubMed ID: 15114266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
    Chou R; Fu R; Huffman LH; Korthuis PT
    Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
    Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
    HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
    J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
    Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
    Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
    Bozzette SA; Ake CF; Tam HK; Chang SW; Louis TA
    N Engl J Med; 2003 Feb; 348(8):702-10. PubMed ID: 12594314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study.
    Nicolatou-Galitis O; Velegraki A; Paikos S; Economopoulou P; Stefaniotis T; Papanikolaou IS; Kordossis T
    Oral Dis; 2004 May; 10(3):145-50. PubMed ID: 15089923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
    Maia BS; Engelson ES; Wang J; Kotler DP
    Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.
    Barreiro P; García-Benayas T; Soriano V; Gallant J
    AIDS Rev; 2002; 4(4):233-41. PubMed ID: 12555697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.
    Wood E; Hogg RS; Yip B; Quercia R; Harrigan PR; O'Shaughnessy MV; Montaner JS
    J Infect Dis; 2003 Nov; 188(10):1421-5. PubMed ID: 14624366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
    Stebbing J; Gazzard B; Mandalia S; Teague A; Waterston A; Marvin V; Nelson M; Bower M
    J Clin Oncol; 2004 Jun; 22(11):2177-83. PubMed ID: 15169806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
    Law MG; Friis-Møller N; El-Sadr WM; Weber R; Reiss P; D'Arminio Monforte A; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Kirk O; Sabin CA; Phillips AN; Lundgren JD;
    HIV Med; 2006 May; 7(4):218-30. PubMed ID: 16630034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.